Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age ≥18 years old;~* Diagnosis of Complex Regional Pain Syndrome (CRPS) using International Association for the Study of Pain criteria \>6 months;~* Normal liver function (AST level \<3x normal level);~* Normal kidney function (serum creatinine \<133µmol/L);~* Full blood count, haematocrit \>38%;~* Willing and able to give informed consent and of completing study questionnaires;~* Stable (no change in past two months) but suboptimal pain pharmacotherapy (i.e. additional pain control felt by patient and physician to be necessary);~* Able to attend research centre according to the visit schedule;~* Women of child-bearing potential must be using a reliable form of contraception i.e. oral contraceptives, a barrier method (condom or diaphragm), intra-uterine device or abstinence.~Exclusion Criteria:~* Optimal response to opioids, antidepressants, anticonvulsants or anti- inflammatory medications;~* Any history or indication of kidney or liver disease;~* Any history of alcohol abuse;~* Presence of diabetes;~* Subjects taking other anti-epileptic drugs, including gabapentin, pregabalin, topiramate, phenytoin, carbamazepine, and oxcarbazepine;~* Pregnancy (a serum bHCG pregnancy test will be performed as part of the initial blood panel);~* Known or suspected allergy to succinimides, ethosuximide, methsuximide (Celontin®), phensuximide;~* Any history of mental illness or disorder, which in the investigators opinion, interferes with the subjects ability to accurately report treatment response;~* Participation in other clinical trial in the 30 days prior to enrolment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).